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Summary--Treatment with antiprogestins is a new treatment modality for breast cancer. 
Previously, in rats with DMBA-induced mammary tumors we observed significant growth 
inhibitory effects of chronic treatment with the antiprogestin mifepristone (RU486). In 
addition, in 11 postmenopausal breast cancer patients, we observed one objective response, 
six instances of short-term stable disease, and four instances of progressive disease. Side-effects 
appeared mainly due to antiglucocorticoid properties of the drug. Increased plasma estradiol 
levels were observed which probably resulted from ovarian (rat) and adrenal (patients) 
steroidogenesis. 
Combined treatment with an antiestrogen in the rat model caused additive growth inhibitory 
effects. Tumor inhibition after single treatment with mifepristone or tamoxifen was 90 and 
75%, respectively. In contrast, when combined, tumor remission similar to that caused by 
LHRH-agonist treatment (50%) was observed. Even higher tumor remission was found after 
combined treatment with mifepristone plus LHRH-agonist (75%). In first studies in the rat 
model we observed significant umor growth inhibitory effects with two new antiprogestins of 
seemingly greater potency which cause less unfavorable ndocrine side-effects. 
In conclusion: combined treatment (antiprogestin plus antiestrogen or LHRH-agonist) may 
be of value in endocrine threapy of breast cancer. 
INTRODUCTION 
Antiprogestins form a new category of anti- 
hormonal agents of potential interest in the 
treatment of cancer. Recently, mifepristone 
(RU486) became available for preclinical 
research and clinical testing. Besides anti- 
progestational properties [1-6], mifepristone has 
antiglucocorticoid activities as well[7-9]. 
Apart from application as a contraceptive 
agent [10-14] or as an antiglucocorticoid n the 
treatment of conditions related to excess corti- 
costeroid production [9], mifepristone may be 
used as a growth inhibitor of several types of 
tumor cells. 
Previously, we reported that different dosages 
of the progestin megestrol acetate caused tumor 
growth inhibition of 40-50%, whereas the anti- 
progestin mifepristone gave rise to 80-90% 
inhibition[15, 16]. This tumor inhibition was 
observed in spite of stimulation of the pitu- 
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itary-ovarian functions, which resulted in un- 
favorable ndocrine ffects (high plasma steroid 
hormone and prolactin levels) [15-17]. Recently, 
we have also reported[18] growth inhibitory 
effects of chronic single treatment with mifepri- 
stone in postmenopausal patients with 
metastatic breast cancer. These inhibitory 
effects were accompanied by unfavorable side- 
effects (i.e. increased plasma estradiol concen- 
trations) due to peripheral conversion of 
androgens derived from hyperstimulated 
adrenals [18]. 
Therefore, the effects of combined treatment 
with mifepristone (to block the PgR) and 
tamoxifen (to block the ER) or LHRH-agonists 
(buserelin or zoladex; to reduce estradiol 
secretion) were investigated. 
MATERIALS AND METHODS 
Precl in ical  studies 
Hormona l  agent solutions. The progestin 
megestrol acetate was obtained from Sigma, 
St Louis, MO. The antiprogestin mifepristone 
(RU486) was generously provided by Roussel- 
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Uclaf (Dr R. Deraedt), Romainville, France. 
Megestrol acetate and micronized mifepristone 
were suspended in olive oil and administered by 
subcutaneous injection (final dosages, see 
Fig. 1). Tamoxifen-citrate was kindly donated 
by ICI (Pharmaceutical Division), Macclesfield, 
Cheshire, U.K. Tamoxifen-citrate was dissolved 
in physiological saline (I mg/ml) and was 
administered subcutaneously (final dosage: 
400#g/kg/day). The LHRH-agonist buserelin 
was generously provided by Hoechst A.G., 
Frankfiirt am Main, F.R.G., in a stock solution 
of 1 mg/ml, or as a 3.3 mg depot-preparation. 
For subcutaneous injections, a work solution 
was made by dilution of the stock solution 
with physiological saline (final dosage: 
40 #g/kg/day). In addition, the LHRH-agonist 
zoladex was kindly provided by ICI (Pharma- 
ceutical Division) as a 3.6 mg implant. Control 
animals received aily injections of saline. 
Treatment of rats. Mammary tumor induc- 
tion was realized by intragastric injection of 
dimethylbenzanthracene (DMBA) as previously 
described [15, 16]. Tumor load of each rat was 
determined [15, 16]. The results of a 3-wk treat- 
ment are expressed as relative (%) tumor load 
values. The relative tumor load value of a rat in 
a certain group is defined as the ratio of its 
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Fig. 1. Relative effects on mammary  tumor load after 
different endocrine treatments for 3wk.  Results are 
means + SEM. The number of animals is indicated in the 
bars. P-value denotes the statistical significance vs control. 
Initial tumor load = 100%. n.s. = Not significant. 
tumor load at the end of treatment (in mm-') and 
the average tumor load of the group as a whole 
(in mm 2) at the start of treatment, and multi- 
plied by 100. After treatment rats were killed by 
decapitation, and mammary tumors, specific 
organs and blood were collected, as de- 
scribed[15, 16]. Steroid receptor and plasma 
hormone assays were performed as de- 
scribed [15, 16]. 
Statistical evaluation of results. The signifi- 
cance of differences between the results obtained 
in the various treatment groups were calculated 
using Wilcoxon's test. 
Clinical studies 
Patients, materials and methods. This study 
was started after approval by a local Human 
Investigations Committee and by the Dutch 
Cancer Society (Protocol KWF-CKVO 86-09). 
Eleven postmenopausal patients (mean age, 
63 yr; range, 46-75 yr) gave informed consent. 
They were treated aily during 3-34 weeks with 
200-400 mg of mifepristone (RU486, Roussel 
Uclaf, France) p.o. as a second-line single treat- 
ment after first-line treatment with tamoxifen, 
irrespective of the response to tamoxifen. In 
four patients, the receptor status of the primary 
tumor was unknown; three patients had an 
[ER +, PgR +] tumor, and four patients an [ER +, 
PgR-] tumor. 
Hematological, biochemical and endocrine 
parameters were studied in 10 patients before 
and after 4, 8, 12 and 16 wk of treatment (for 
more details, see [18]). Skin and Lymph node 
metastases were measured every 4 wk. X-rays of 
specific bone and lung lesions were performed 
every 3 months. Bone scans were performed 
before and a half year after start of treatment. 
Scoring of response occurred according to Inter- 
national Union against Cancer criteria. For 
statistical methods, we used a Student's paired 
t-test and the non-parametric method of 
Wilcoxon. 
RESULTS 
Preclinical studies 
It was found that both LHRH-agonist im- 
plants (buserelin and zoladex) caused similar 
effects on all parameters studied with regard to 
both the direction (inhibitory or stimulatory) 
and magnitude of the effects. Therefore, the 
results with these implants were combined. 
Effects of treatments on tumor growth. Treat- 
ment with the progestin megestrol acetate 
Treatment ofbreast cancer with different antiprogestins 791 
resulted in approx. 40% tumor growth 
inhibition (Fig. 1). Single tamoxifen treatment 
and mifepristone treatment resulted in a 
considerable inhibition of tumor growth of 
approx. 75 and 90% respectively, but not in 
tumor remission. Combined antiprogestational 
and antiestrogenic treatment with mifepristone 
and tamoxifen gave rise to a remission of tumor 
growth by 50%, indicating additive inhibitory 
effects (Fig. 1). The same tumor regression was 
also observed after single treatment with 
LHRH-agonist administered by injection 
(buserelin). Single LHRH-agonist treatment 
using implants (buserelin or zoladex) was 
significantly more efficacious in causing tumor 
remission than by treatment with daily injec- 
tions of buserelin (remission by 70 vs 50%, 
respectively, P <0.03; [19]). Finally, combi- 
nation treatment with mifepristone and daily 
LHRH-agonist injections (buserelin) resulted in 
significantly greater tumor growth inhibitory 
effects than single treatment with LHRH- 
agonist injections (approx. 75 vs 50% tumor 
remission, respectively, P < 0.002; [19]). When 
mifepristone was combined with LHRH-agonist 
implants, such a combination did not result 
in a significantly greater antitumor effect 
than single treatment with LHRH-agonist im- 
plants. 
Effects on mean plasma hormone concen- 
trations. We have previously described that 
mifepristone treatment caused increased plasma 
levels of LH, estradiol and progesterone, 
whereas FSH levels were not significantly 
affected[15, 16]. In subsequent studies FSH 
levels were significantly suppressed by 37% 
(P <0.005; [19]), while plasma concentrations 
of progesterone were not significantly different 
from those in control animals. After tamoxifen 
treatment all plasma hormone levels studied 
were decreased. Combined treatment with 
mifepristone and tamoxifen resulted in plasma 
hormone concentrations which were in between 
those obtained after treatment with only 
mifepristone or tamoxifen: estradiol and pro- 
gesterone l vels were unchanged, and LH levels 
were increased compared to control. However, 
this increase in plasma LH level was signifi- 
cantly less pronounced (P < 0.0035) than after 
single treatment with mifepristone [19]. 
LHRH-agonists were administered by subcu- 
taneous injections or implants[19]. LHRH- 
agonist treatment by injections resulted in 
increased levels of LH (30-fold) and FSH (2-3- 
fold), whereas treatment with LHRH-analog 
implant caused no significant change in LH 
levels and significantly decreased FSH levels. 
The decreases in plasma steroid hormone levels 
were more pronounced after treatment with 
LHRH-agonist implants than after its injection 
(E2, P < 0.02; Pg, P < 0.005). In combination 
with mifepristone, the effects of treatments on 
plasma hormone concentrations were compar- 
able to those caused by the LHRH-agonist. 
Effects on organ weights and steroid receptor 
contents of the mammary tumors. For details on 
these effects of treatments we refer to [19]. Cyto- 
solic tumor ER contents were decreased by all 
treatment modalities. Tumor PgR contents 
tended to increase after tamoxifen treatment 
and were significantly decreased after mifepris- 
tone treatment. Mifepristone treatment made 
the tumors nearly PgR-negative. Treatment 
with LHRH-agonist implants caused lower ster- 
oid hormone receptor contents than with daily 
injections of LHRH-agonist. Cytosolic tumor 
PgR level was virtually undetectable after com- 
bined treatment with mifepristone and injected 
LHRH-agonist. 
Effects of new antiprogestins on tumor growth. 
A comparison of the antitumor effects of 
mifepristone with those of two new anti- 
progestins ORG31710 and ORG31806 is shown 
in Fig. 2. It was found that treatment with the 
same dosage of either of these three 
antiprogestins gave rise to a considerable 
inhibition of tumor growth (mifepristone, 
ORG31806) and even to a slight tumor remis- 
sion (ORG31710). However, the differences be- 
tween the antitumor effects of the antiprogestins 
were not statistically significant. 
Clinical studies 
Antitumor effects. One of 11 patients howed 
a partial response of her lymph node metastases 
(58% decrease of tumor size) lasting 5 months; 
six patients howed stable disease of 3-8 month 
duration; and four, progressive disease from 
start of treatment (Table l). Anorexia and a 
slight degree of nausea (8 times); tiredness (6 
times), not feeling well and dizzziness (4 times) 
and somnolence (4 times) were relatively fre- 
quent complaints (Table 1). 
Side-effects generally did not occur in the first 
week of treatment, but sometimes after weeks or 
months of treatment, suggesting that certain 
plasma levels of mifepristone have to be reached 
before side-effects occur. Ten patients howed a 
decrease in body weight (mean, 3 kg; range, 
0.9-7.5 kg), while patient I l had an initial body 
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Fig. 2. Relative effects on mammary tumor load after different endocrine treatments for 3 wk with 
2 x 1 mg/day of ORG31710, ORG31806 or RU486. Results are means + SEM. Below the figure are 
indicated the number of rats and the statistical significance vs control: *P < 0.05, 8,p < 0.01, *P < 0.005. 
The initial tumor load = 100%. 
weight increase of 5 kg which was followed by 
a decrease of 2 kg without other side-effects. We 
did not observe significant effects on blood 
pressure. However, one patient using anti- 
hypertensive drugs before treatment no longer 
required antihypertensive treatment after the 
start of treatment with mifepristone. 
Two patients had to stop treatment with 
mifepristone because of side-effects (in the 
absence of tumor progression). One of these 
patients was hospitalized because of a grand mal 
seizure and subcoma under suspicion of cerebral 
metastases. Treatment with dexamethasone was 
instituted and mifepristone treatment was 
stopped. However, on the computed tomogra- 
phy scan of the cerebrum, metastases were not 
found, and the patient improved remarkably 
after 3 days and was dismissed from the hospital 
Table 1. Antitumor and side-effects of second-line ndocrine treat- 
ment with mifepristone of II postmenopausal patients with 
metastatic breast cancer 
Antitumor effects 
Objective response (CR + PR) = 1 x 
Stable disease = 6 × (3-8 months) 
Progressive disease = 4 x 
Side-effects 
Anorexia = 8 × 
Nausea = 8 x 
Dizziness = 4 x 
Tiredness = 6 x 
Sopor = 4 x 
Epileptic insult = ! x 
Reduction in body weight = mean 3 kg (range 0.9-7.5 kg) 
Blood pressure = no effect 
without physical complaints. These obser- 
vations suggest that this complication was 
initiated by mifepristone. In view of the long 
half-life of mifepristone of about 20h, the 
improvement might be related to both excretion 
of mifepristone and treatment with high-dose 
dexamethasone that overcame the antigluco- 
corticoid activity of the gradually decreasing 
plasma levels of mifepristone. 
Endocrine effects. In addition to plasma 
ACTH, plasma cortisol concentrations showed 
a highly significant increase during treatment, 
indicating stimulation of the pituitary-adrenal 
axis[18]. In contrast o a normal increase of 
plasma cortisol concentrations by stimulation 
with synacthen before treatment, there was no 
significant change of the increased basal cortisol 
levels by synacthen during mifepristone 
treatment. Moreover, the increased basal corti- 
sol concentrations could not be suppressed by 
l mg of dexamethasone during mifepristone 
treatment [18]. Surprisingly, plasma ndrostene- 
dione and especially plasma estradiol levels 
increased significantly during treatment. We 
found no significant effects on basal and 
stimulated gonadotropin concentrations, while 
plasma SHBG concentrations lightly de- 
creased. Plasma estradiol concentrations were 
positively correlated with plasma androstene- 
dione (P < 0.05) and cortisol concentrations 
(P < 0.01). Basal prolactin levels did not change 
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during mifepristone treatment, while thyro- 
tropin-releasing hormone-stimulated plasma 
prolactin concentrations tended to increase, 
possibly in relation to the increased estradiol 
levels. 
DISCUSSION 
We have previously demonstrated in exper- 
imental breast cancer studies that mifepristone 
is a more potent tumor growth inhibitor than 
the progestin megestrol acetate in rats bearing 
DMBA-induced mammary tumors[15, 16]. In 
addition, it was found that the antitumor effect 
of mifepristone was not different from that of 
the antiestrogen tamoxifen[19]. The tumor 
growth inhibitory effects of mifepristone oc- 
curred in spite of increased plasma concen- 
trations of estradiol (and prolactin; cf. [15]) as a 
consequence of stimulation of the pituitary- 
ovarian axis[15, 16]. Also, in postmenopausal 
women with metastatic breast cancer, chronic 
single second- or third-line treatment with 
mifepristone caused tumor growth inhibitory 
effects [18, 19]. In our group of postmenopausal 
patients, and similar to the results in the rat, 
these inhibitory effects were observed in spite 
of increased estradiol concentrations [18]. The 
latter was caused presumably by stimulation of 
the pituitary-adrenal xis, followed by periph- 
eral conversion of adrenal androgens into estro- 
gens[18]. These observations, together with 
those of direct growth inhibition of cultured 
mammary tumor cells [1-3, 16], indicate that the 
main mechanism of action of antiprogestational 
treatment is a direct growth inhibitory effect at 
the level of the mammary tumor cells. The 
effects of combined treatment with mifepristone 
(to block the PgR) and tamoxifen (aiming also 
at blockade of the ER), or with mifepristone 
and an LHRH-agonist (to decrease strogen 
secretion) indicate that combined antiproges- 
tational-antiestrogenic treatment with mifepris- 
tone plus tamoxifen was superior to treatment 
with either drug alone, i.e. combined treatment 
resulted in strong tumor remission compared to 
only tumor growth inhibition, but no remission, 
after treatment with either agent[19]. Pre- 
viously, additive growth inhibitory effects on 
breast cancer cells were observed in vitro with 
certain concentrations of mifepristone and 
tamoxifen [2]. 
Interestingly, treatment of rats bearing 
DMBA-induced mammary tumors with two 
new antiprogestins (i.e. ORG31710 and 
ORG31806) at even lower dosages than the 
10mg/kg/day previously used, resulted in a 
slight tumor remission. The balance of anti- 
tumor effects and unfavorable ndocrine ffects 
appeared improved on the basis of increased 
antitumor activities and seemingly reduced 
endocrine side-effects (not shown) of these new 
antiprogestins. The antitumor activity and the 
mechanism of action of other antiprogestins, 
such as onapristone, have been described by 
Schneider et al. [21] in studies of the DMBA- or 
MNU-induced mammary tumors in the rat. 
It is concluded that in treatment with mifepri- 
stone, the additional blockade of the tumor ER 
by tamoxifen or the decrease in plasma steroid 
hormone levels caused by LHRH-agonists, pre- 
vented the unfavorable ndocrine effects re- 
sulting from single treatment with mifepristone. 
The combined effects result in a more pro- 
nounced tumor growth inhibition during com- 
bined endocrine treatment. Moreover, new 
antiprogestins (and their combinations with 
other hormonal agents) will be tested for the 
appreciation of their therapeutic values in the 
treatment of human breast cancer. 
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